Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Fulcrum Therapeutics Inc (NASDAQ: FULC) closed at $8.69 down -0.69% from its previous closing price of $8.75. In other words, the price has decreased by -$0.69 from its previous closing price. On the day, 0.53 million shares were traded. FULC stock price reached its highest trading level at $8.78 during the session, while it also had its lowest trading level at $8.45.
Ratios:
For a deeper understanding of Fulcrum Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 24.42 and its Current Ratio is at 24.42. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on July 29, 2025, Upgraded its rating to Buy and sets its target price to $12 from $4 previously.
On May 23, 2025, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform but kept the price unchanged to $12.
Cantor Fitzgerald Upgraded its Neutral to Overweight on May 15, 2025, while the target price for the stock was maintained at $10.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 08 ’25 when Tourangeau Greg sold 498 shares for $5.06 per share. The transaction valued at 2,520 led to the insider holds 14,062 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FULC now has a Market Capitalization of 473301376 and an Enterprise Value of 263515904.
Stock Price History:
The Beta on a monthly basis for FULC is 3.04, which has changed by 1.4005525 over the last 52 weeks, in comparison to a change of 0.13724327 over the same period for the S&P500. Over the past 52 weeks, FULC has reached a high of $9.88, while it has fallen to a 52-week low of $2.32. The 50-Day Moving Average of the stock is 15.41%, while the 200-Day Moving Average is calculated to be 54.28%.
Shares Statistics:
For the past three months, FULC has traded an average of 627.01K shares per day and 446970 over the past ten days. A total of 54.09M shares are outstanding, with a floating share count of 47.95M. Insiders hold about 11.36% of the company’s shares, while institutions hold 91.01% stake in the company. Shares short for FULC as of 1759190400 were 3349875 with a Short Ratio of 5.34, compared to 1756425600 on 3721073. Therefore, it implies a Short% of Shares Outstanding of 3349875 and a Short% of Float of 8.939999.
Earnings Estimates
Fulcrum Therapeutics Inc (FULC) is presently subject to a detailed evaluation by 8.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.3, with high estimates of -$0.27 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$1.06 and -$1.24 for the fiscal current year, implying an average EPS of -$1.14. EPS for the following year is -$1.19, with 8.0 analysts recommending between -$1.02 and -$1.33.
